{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134656","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.524206+00:00","generated_at":"2026-05-15T08:13:53.463841+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs","bullets":["Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.","CVR milestones: $2 for first US NDA of ORX750/ORX142 by Dec 31, 2029; $5 for IH approval within 5 yrs; $2 for NT2 approval within 5 yrs.","Supporting shareholders owning ~20% of shares agreed to vote in favor of the scheme.","Transaction expected to close by Sept 30, 2026, extendable to March 31, 2027 for HSR clearance.","Termination fee of ~$63M payable by Centessa under certain circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134656","json":"https://secwatch.observer/filing/0001193125-26-134656.json","markdown":"https://secwatch.observer/filing/0001193125-26-134656.md","text":"https://secwatch.observer/filing/0001193125-26-134656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/0001193125-26-134656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/d145970d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:13:53.463841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2477d89030cbdabe20bc571fd203f15716fb707c","claim":"Centessa Pharmaceuticals plc entered into Transaction Agreement with Eli Lilly and Company and LDH XV Corporation (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (the “Company”), entered into a Transaction Agreement (the “Transaction Agreement”) with Eli Lilly and Company, an Indiana corporation (“Parent”), and LDH XV Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/0001193125-26-134656-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Eli Lilly and Company and LDH XV Corporation"},{"label":"Effective","value":"2026-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}